Equally important is avoiding overestimation of risk and preventing withholding of lifesaving BTK inhibitor treatment in patients who are not truly high risk, and future prospective validation studies should include those with a history of CVD including CHF, coronary artery disease, and ventricular arrythmias that are well compensated. Here, BTK is linked to congestive heart failure.